 phase new cisplatin derivative hematologic malignancies DWA new derivative platin compounds Phase II studies solid tumors Japan dose-limiting factor myelotoxicity mild extramedullary toxicity Phase adult patients relapsed hematologic malignancies patients total treatment courses DWA dose hours continuous infusion dose Clinical toxicity urinary excretion studies DWA successive days type administration days diarrhea nausea vomiting parenteral fluids nutritional support dose-limiting factor schedule gastrointestinal toxicity Myelotoxicity tolerable patients acute nonlymphocytic leukemia ANLL complete remission patient chronic myelogenous leukemia CML crisis chronic phase Phase II trial DWA hematologic malignancies myeloid diseases